Novartis Ag

Yunsheng He

Donald Johns

Baltazar Gomez-Mancilla

Kevin Hall McAllister

Cristina Lopez-Lopez

Markus Weiss

Nicole Pezous

Lisa Sandford

Dominik Feuerbach

Kevin Hall Mcallister

Joy Gispati Ghosh

Christian Leisner

Michael Wald

Georges Weissgerber

The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.

Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment

The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNFα antagonist, e.g., a TNFα antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNFα antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636.

Methods of treating dry eye disease using TNF alpha antagonists

The invention features methods of identifying patients as being likely to respond to anti-VEGF therapy. Furthermore, in those patients identified as failing to include one or more of the above ophthalmic response markers, the invention features treatment with an EPO antagonist (e.g., alone, or in combination with a VEGF antagonist).

Methods of treating ophthalmic disorders

Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment

Growing community of inventors

Cambridge, MA, United States of America

Yunsheng He